Better Access. Better Lives.
Who we are?
We are passionate people, working to improve patient lives and the sustainability of the global healthcare ecosystem by broadening the availability and accessibility of biosimilars.
We believe that a vertically integrated approach, from cell line development through fill and finish manufacturing, gives us the control, scale and speed needed to achieve our mission. We maintain our singular focus on what we do best while relying on the deep expertise of our partners for commercialization.
We are committed to developing and manufacturing high-quality, cost-competitive biosimilars. We continually evaluate additional pipeline opportunities to bring a strategic and robust selection of biologic medicines to patients around the world.
Alvotech, a Global Pureplay Biosimilars Company, to Debut on Nasdaq Under the Ticker ALVO on June 16
STADA and Alvotech broaden European patients’ options by launching Hukyndra® high-concentration, citrate-free adalimumab
Alvotech and Oaktree Acquisition Corp.II Announce Shareholder Approval of Business Combination
Join our team
Here at Alvotech, we want our employees to feel inspired in their careers and challenged by interesting and meaningful work. That’s why we are proud of our purpose-driven culture. We are always interested in speaking to passionate, experienced individuals. Are you ready to join our growing team?